Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/09/2018 10/10/2018 10/11/2018 10/12/2018 10/15/2018 Date
16.77(c) 15.77(c) 15.62(c) 16.5(c) 16.08 Last
2 125 737 1 688 132 2 583 184 2 968 307 1 276 541 Volume
+1.05% -5.96% -0.95% +5.63% -2.55% Change
More quotes
Financials (EUR)
Sales 2018 350 M
EBIT 2018 43,9 M
Net income 2018 33,9 M
Debt 2018 80,0 M
Yield 2018 -
Sales 2019 394 M
EBIT 2019 59,8 M
Net income 2019 43,3 M
Debt 2019 34,3 M
Yield 2019 -
P/E ratio 2018 68,75
P/E ratio 2019 51,97
EV / Sales2018 7,19x
EV / Sales2019 6,27x
Capitalization 2 435 M
More Financials
Company
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies.It operates through the EVT Execute and EVT Innovate segments.The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes... 
More about the company
Surperformance© ratings of Evotec AG
Trading Rating : Investor Rating :
More Ratings
Latest news on EVOTEC AG
10/11EVOTEC : And celgene expand ipsc collaboration to include additional cell lines
EQ
10/09EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
10/09EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
10/05EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
10/04EVOTEC : Signs agreement with sanofi to advance early stage academic research in..
EQ
10/02EVOTEC AG : Notification and public disclosure of transactions by persons
EQ
09/28EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
09/26EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
09/19EVOTEC : and Almirall enter into research collaboration in the field of dermatol..
AQ
09/17EVOTEC : And almirall enter into research collaboration in the field of dermatol..
EQ
More news
Sector news : Biotechnology & Medical Research - NEC
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More sector news : Biotechnology & Medical Research - NEC
MarketScreener Strategies on EVOTEC AG 
EVOTEC AG - 2017
A good level to buy
BUY
More Strategies
Latest Tweets
10/11EVOTEC AND CELGENE EXPAND IPSC COLLABORATION TO INCLUDE ADDITIONAL CELL LINES..
2
10/09Evotec AG: Release according to Article 40, Section 1 of the WpHG [the German.. 
10/09Evotec AG: Release according to Article 40, Section 1 of the WpHG [the German.. 
10/05Evotec and Sanofi Join to Further Cutting-Edge Therapeutic Drug Discovery: Ye.. 
10/05Sanofi teams up with Evotec in drug discovery  
More tweets
Qtime:54
News from SeekingAlpha
10/05Sanofi teams up with Evotec in drug discovery 
08/27CENTOGENE and Evotec sign global strategic partnership on drug discovery proj.. 
08/12Evotec AG 2018 Q2 - Results - Earnings Call Slides 
08/12Evotec AG (EVOTF) CEO Werner Lanthaler on Q2 2018 Results - Earnings Call Tra.. 
08/09Evotec AG reports Q2 results 
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 23,1 €
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Eugenio Cosimino Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG22.22%2 815
CELLTRION, INC.--.--%30 463
IQVIA HOLDINGS INC27.47%24 833
LONZA GROUP18.72%23 465
INCYTE CORPORATION-33.95%13 127
SEATTLE GENETICS, INC.36.02%11 255